The second application shows a prospective DDI simulation between a marketed antimalarial combination, artemether‐lumefantrine (AL), and the rifamycin antibiotic, rifabutin, a moderate CYP3A4 inducer, which can be used to treat TB. Here, CYP3A4 is linked to tuberculosis.